Fig. 2

PCDH17 expression in AML and normal hematopoiesis. a, b Box plots illustrating the validation of PCDH17 expression changes in AML in three independent datasets. a Datasets using CD34 + cells from normal controls and AML patients, as indicated. b Dataset using whole bone marrow cells from normal controls and AML patients, as indicated. c Box plots showing that PCDH17 expression is significantly lower in patients with AML in comparison to HSC and PMN from healthy donors, using a large aggregated data set (BloodPool) from the BloodSpot website (http://servers.binf.ku.dk/bloodspot/). d Box plot comparing PCDH17 expression levels in normal controls and AML as assessed by RT-qPCR. Comparisons were made by the Wilcoxon rank-sum test. e Box plot showing the expression pattern of PCDH17 during differentiation of the major hematopoietic lineages using published dataset (GSE42519). f Box plot showing the expression pattern of PCDH17 during differentiation of the major hematopoietic lineages using a merged data set (HemaExplorer) from the BloodSpot website (http://servers.binf.ku.dk/bloodspot/). HSC hematopoietic stem cell, MPP multipotent progenitor, CMP common myeloid progenitor, GMP granulocyte-monocyte progenitor, MEP megakaryocyte-erythrocyte progenitor, PM promyelocyte, MY myelocyte, MM metamyelocytes, BC band cell, PMN polymorphonuclear cells, HPC hematopoietic progenitor cells, BM bone marrow, PB peripheral blood